Dupilumab shows good drug survival at one, two, and three years of treatment for atopic dermatitis (AD), according to a study published online Aug. 10 in JAMA Dermatology .

Lotte S. Spekhorst, M.D., from the University Medical Center Utrecht in the Netherlands, and colleagues describe drug survival of dupilumab and associated predictors in patients with AD using data from the multicenter prospective BioDay registry. Data were included for 715 adult patients.

The researchers found that the one-, two-, and three-year overall dupilumab drug survival was 90.3, 85.9, and 78.6 percent, respectively, among the patients. Use of immunosuppressant drugs at baseline and being a nonresponder at four weeks were characteristics associated with shorter drug survival owing to ineffectiveness (hazard ratios, 2.64 and 8.68, respectively). Use of immunosuppressant drugs at baseline, age 65 years or older, and an Investigator Global Assessment score of very severe AD were characteristics associated with shorter drug survival owing to adverse effects (hazard ratios, 2.69, 2.94, and 3.51, respectively).

"In the coming years, daily practice registry data will provide longer follow-up data of new advanced systemic treatments, which will give information on dupilumab drug survival compared with these new systemic treatments," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi and Regeneron, the manufacturers of dupilumab; patients in this study participated in the BioDay registry, which was sponsored by Sanofi Genzyme.

Abstract/Full Text (subscription or payment may be required)